The shift is not simply about producing more medicines locally; it is about developing the capabilities to participate more deeply in the global pharmaceutical and biopharmaceutical value chain.

The direction is clear. Saudi Arabia’s National Biotechnology Strategy aims to establish the Kingdom as the leading biotechnology hub in the Middle East and North Africa by 2030 and a global biotechnology hub by 2040. Biomanufacturing and localisation sit at the heart of this ambition, alongside vaccines, genomics and capabilities that can support domestic demand and regional exports.

For Saudi pharmaceutical manufacturers, this transformation is redefining what localisation can mean.

Moving beyond conventional manufacturing

Building a competitive biotechnology sector requires a strong industrial foundation.

SPIMACO has spent four decades developing pharmaceutical manufacturing capabilities in Saudi Arabia. Today, its manufacturing base includes the Al-Qassim Industrial Complex, producing multiple dosage forms ranging from oral solids and sterile products to high-potency medicines.

The addition of specialised capabilities is increasingly important. SPIMACO’s High-Potent Facility, which began commercial production in 2025, supports the manufacture of high-potency tablets and capsules, including medicines used in targeted cancer treatment and other critical diseases.

Localisation is also moving further upstream in the pharmaceutical value chain. Through CAD Middle East in Riyadh, SPIMACO has capabilities in active pharmaceutical ingredient production, supported by in-house research and development, process optimisation and technology transfer.

Together, these capabilities provide an industrial platform for a broader transition: from manufacturing established medicines locally to participating in increasingly complex areas of pharmaceutical and biopharmaceutical production.

Building capabilities in biologics and advanced therapies

Biotechnology represents the next stage of this transition.

The establishment of SPIMACO Bio reflects a strategic move towards building national capabilities in biologics and advanced therapies. SPIMACO aspires to become a national biotechnology enabler, supporting the Kingdom’s ambition to build a globally competitive biotechnology ecosystem, connect international innovation with local capabilities and expand patient access to advanced therapies across Saudi Arabia and the wider region.

This ambition extends beyond bringing global innovation into the market. It is also about creating sustainable capabilities through knowledge and technology transfer, developing local expertise and establishing pathways towards future localisation and manufacturing.

International partnerships are central to this model. SPIMACO’s collaboration with GENETIX Biotherapeutics, for example, creates a pathway towards bringing gene therapies for sickle cell disease and beta-thalassaemia to the region, alongside future localisation and knowledge transfer. These diseases are particularly relevant to populations across the Middle East and demonstrate how local capability building could bring highly specialised therapies closer to patients.

SPIMACO is also expanding its presence in biologics through partnerships covering biosimilar therapies, including PD-1 inhibitors in oncology, alongside opportunities to localise complex biologic medicines such as aflibercept.

Taken together, these developments point to a broader shift in localisation: from increasing the volume of medicines produced domestically to developing the technical, regulatory and manufacturing expertise required to participate more deeply in global biopharmaceutical value chains.

Technology transfer as a catalyst

For emerging pharmaceutical ecosystems, sustainable localisation depends on more than physical production capacity.

Technology transfer can build expertise across manufacturing processes, quality systems, regulatory requirements and specialised scientific disciplines. It can also create an environment in which international pharmaceutical and biotechnology companies view Saudi Arabia not only as a commercial market, but as a potential platform for regional manufacturing and collaboration.

For established Saudi manufacturers, global partnerships can therefore serve two purposes: accelerating patient access to innovation today while developing the local knowledge and infrastructure required for greater participation in innovation tomorrow.

From local production to a regional hub

The opportunity extends beyond Saudi Arabia’s domestic pharmaceutical market.

An integrated ecosystem combining advanced manufacturing, APIs, biotechnology, technology transfer, research, regulatory capabilities and specialised healthcare could strengthen the Kingdom’s ability to serve pharmaceutical demand across the Middle East and North Africa.

It could also have important implications for patient access. As capabilities in oncology, rare diseases, genetic disorders and advanced therapies develop, Saudi Arabia has an opportunity to connect pharmaceutical innovation with its expanding specialised healthcare infrastructure. Over time, these developments could also contribute to the Kingdom’s emergence as a destination for specialised treatment and medical tourism, while giving patients across the region greater access to complex and advanced therapies closer to home.

The transition from localisation to biotechnology will not happen through manufacturing capacity alone. It requires international collaboration, sustained technology transfer and the development of specialised expertise across the pharmaceutical value chain.

For SPIMACO, this evolution builds on four decades of manufacturing experience while opening a new chapter centred on biologics, advanced therapies and global partnerships. For Saudi Arabia, it represents something larger: an opportunity to move from being a major pharmaceutical market to becoming an increasingly important contributor to the regional and ultimately global biotechnology ecosystem.